Select publications

Coen JJ et al. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 2002;20(15):3199-205. Abstract

D’Amico AV et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292(7):821-7. Abstract

Eisenberger MA et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Proc ASCO 2004;Abstract 4.

Petrylak DP et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (p) in men with androgen-independent prostate cancer (AIPCA). Proc ASCO 2004;Abstract 3.

Roach M 3rd et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21(10):1904-11. Abstract

Salminen EK et al. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004;10(22):7575-82. Abstract

Stock RG et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy 2002;1(2):83-9. Abstract